The awards were granted under the Pyxis Oncology, Inc. 2022 Inducement Plan (the ‘Plan’) with a grant date of September 30, 2025, as an inducement material to the new employee entering employment with Pyxis Oncology, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have a ten-year term and an exercise price of $2.22, the closing price of Pyxis Oncology’s common stock as reported by Nasdaq on September 30, 2025. Pyxis Oncology is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4). About Pyxis Oncology, Inc.Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. Pyxis Oncology ContactJitu WadhanePrincipal Financial and Accounting [email protected]